Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC
Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They presently have a $22.00 price target on the stock. Needham & Company LLC’s target price indicates a potential upside of 136.56% from the company’s previous close. […]
Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They presently have a $22.00 price target on the stock. Needham & Company LLC’s target price indicates a potential upside of 136.56% from the company’s previous close. […]
